Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
Zentalis Pharmaceuticals (NASDAQ: ZNTL) has announced the acceptance of an abstract for poster presentation at the 2025 ASCO Annual Meeting in Chicago from May 30 to June 3, 2025. The presentation will showcase clinical data from their ongoing Phase 1/2 trial of azenosertib, their WEE1 inhibitor, in combination with encorafenib and cetuximab for treating patients with metastatic BRAF V600E mutant colorectal cancer.
The poster presentation, titled 'Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib,' will be presented by Dr. Jeanne Tie on Saturday, May 31, 2025, from 9:00 a.m. to 12:00 p.m. CDT. The data cutoff date for the presentation is April 4, 2025. The poster will be available on the Zentalis website under the 'Supporting Publications' tab in the 'Our Approach' section.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) ha annunciato l'accettazione di un abstract per una presentazione poster al 2025 ASCO Annual Meeting che si terr脿 a Chicago dal 30 maggio al 3 giugno 2025. La presentazione mostrer脿 i dati clinici del loro trial di Fase 1/2 in corso su azenosertib, un inibitore di WEE1, in combinazione con encorafenib e cetuximab per il trattamento di pazienti con carcinoma colorettale metastatico con mutazione BRAF V600E.
Il poster, intitolato 'Risultati dell'escalation di dose di Fase 1 dell'inibitore WEE1, azenosertib', sar脿 presentato dalla Dott.ssa Jeanne Tie sabato 31 maggio 2025, dalle 9:00 alle 12:00 CDT. La data di cutoff dei dati per la presentazione 猫 il 4 aprile 2025. Il poster sar脿 disponibile sul sito di Zentalis nella sezione 'Supporting Publications' sotto la scheda 'Our Approach'.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) ha anunciado la aceptaci贸n de un resumen para la presentaci贸n de un p贸ster en la Reuni贸n Anual ASCO 2025 en Chicago, del 30 de mayo al 3 de junio de 2025. La presentaci贸n mostrar谩 datos cl铆nicos de su ensayo en curso de fase 1/2 con azenosertib, su inhibidor de WEE1, en combinaci贸n con encorafenib y cetuximab para tratar a pacientes con c谩ncer colorrectal metast谩sico con mutaci贸n BRAF V600E.
El p贸ster, titulado 'Resultados de la escalada de dosis de fase 1 del inhibidor WEE1, azenosertib', ser谩 presentado por la Dra. Jeanne Tie el s谩bado 31 de mayo de 2025, de 9:00 a.m. a 12:00 p.m. CDT. La fecha l铆mite de datos para la presentaci贸n es el 4 de abril de 2025. El p贸ster estar谩 disponible en el sitio web de Zentalis bajo la pesta帽a 'Supporting Publications' en la secci贸n 'Our Approach'.
Zentalis Pharmaceuticals (NASDAQ: ZNTL)電� 2025雲� 5鞗� 30鞚茧秬韯� 6鞗� 3鞚缄箤歆� 鞁滌勾瓿犾棎靹� 鞐措Μ電� 2025 ASCO 鞐半須岇潣鞐愳劀 韽姢韯� 氚滍憸 齑堧鞚� 毂勴儩霅橃棃鞚岇潉 氚滍憸頄堨姷雼堧嫟. 鞚措矆 氚滍憸鞐愳劀電� 歆勴枆 欷戩澑 1/2靸� 鞛勳儊鞁滍棙鞐愳劀 WEE1 鞏奠牅鞝滌澑 azenosertib毳� encorafenib 氚� cetuximab瓿� 氤戩毄頃橃棳 BRAF V600E 霃岇棸氤�鞚� 鞝勳澊靹� 雽�鞛レ晹 頇橃瀽毳� 旃橂頃� 鞛勳儊 雿办澊韯半ゼ 靹犽炒鞚� 鞓堨爼鞛呺媹雼�.
'WEE1 鞏奠牅鞝� azenosertib鞚� 1靸� 鞖╇焿 歃濍焿 瓴瓣臣'霛茧姅 鞝滊鞚� 韽姢韯半姅 2025雲� 5鞗� 31鞚� 韱犾殧鞚� 鞓れ爠 9鞁滊秬韯� 12鞁滉箤歆� CDT 鞁滉皠鞐� Jeanne Tie 氚曥偓臧� 氚滍憸頃╇媹雼�. 氚滍憸毳� 鞙勴暅 雿办澊韯� 旎缝槫頂� 雮犾電� 2025雲� 4鞗� 4鞚检瀰雼堧嫟. 頃措嫻 韽姢韯半姅 Zentalis 鞗轨偓鞚错姼鞚� 'Our Approach' 靹轨厴 雮� 'Supporting Publications' 韮棎靹� 頇曥澑頃� 靾� 鞛堨姷雼堧嫟.
Zentalis Pharmaceuticals (NASDAQ : ZNTL) a annonc茅 l'acceptation d'un r茅sum茅 pour une pr茅sentation par affiche lors du Congr猫s annuel ASCO 2025 脿 Chicago, du 30 mai au 3 juin 2025. La pr茅sentation mettra en avant les donn茅es cliniques de leur essai de phase 1/2 en cours sur azenosertib, leur inhibiteur de WEE1, en combinaison avec encorafenib et cetuximab pour le traitement des patients atteints d'un cancer colorectal m茅tastatique avec mutation BRAF V600E.
L'affiche, intitul茅e 芦 R茅sultats de l'escalade de dose en phase 1 de l'inhibiteur WEE1, azenosertib 禄, sera pr茅sent茅e par le Dr Jeanne Tie le samedi 31 mai 2025, de 9h00 脿 12h00 CDT. La date de coupure des donn茅es pour la pr茅sentation est le 4 avril 2025. L'affiche sera disponible sur le site web de Zentalis dans l'onglet 芦 Supporting Publications 禄 de la section 芦 Our Approach 禄.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) hat die Annahme eines Abstracts f眉r eine Posterpr盲sentation auf dem 2025 ASCO Annual Meeting in Chicago vom 30. Mai bis 3. Juni 2025 bekanntgegeben. Die Pr盲sentation wird klinische Daten aus ihrer laufenden Phase-1/2-Studie mit azenosertib, ihrem WEE1-Inhibitor, in Kombination mit Encorafenib und Cetuximab zur Behandlung von Patienten mit metastasiertem kolorektalem Krebs mit BRAF V600E-Mutation zeigen.
Das Poster mit dem Titel 鈥濸hase-1-Dosiseskalationsergebnisse des WEE1-Inhibitors azenosertib鈥� wird am Samstag, den 31. Mai 2025, von 9:00 bis 12:00 Uhr CDT von Dr. Jeanne Tie pr盲sentiert. Der Datenstichtag f眉r die Pr盲sentation ist der 4. April 2025. Das Poster wird auf der Zentalis-Website unter dem Reiter 鈥濻upporting Publications鈥� im Bereich 鈥濷ur Approach鈥� verf眉gbar sein.
- Potential first-in-class and best-in-class WEE1 inhibitor development
- Progress in Phase 1/2 clinical trial with data ready for presentation
- None.
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis庐 Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL.
The poster will include clinical data as of an April 4, 2025 data cutoff from the Company鈥檚 ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in patients with metastatic BRAF V600E mutant colorectal cancer.
Abstract and poster presentation details are below:
Title: 鈥淧hase 1 dose escalation results of the WEE1 inhibitor, azenosertib, in combination with encorafenib and cetuximab in patients with previously treated BRAF V600E mutant metastatic colorectal cancer鈥�
Abstract Number: 3551
Poster Session: Gastrointestinal Cancer 鈥� Colorectal and Anal
Poster Board: 372
Date/Time: Saturday, May 31, 2025, 9:00 a.m. - 12:00 p.m. CDT
Presenter: Dr. Jeanne Tie
The poster can be accessed through the 鈥淪upporting Publications鈥� tab on the 鈥淥ur Approach鈥� section of the on the day of the presentation.
About Azenosertib
Azenosertib is a novel, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated as a monotherapy and combination clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage and leading to mitotic catastrophe and cancer cell death.
About Zentalis Pharmaceuticals
Zentalis庐听Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit听. Follow Zentalis on X/Twitter at听听and on LinkedIn at听.
ZENTALIS庐 and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.听
Contact:听
Haibo Wang听- Chief Business Officer
Ron Moldaver - Investor Relations
听
FAQ
What clinical trial data will Zentalis (ZNTL) present at ASCO 2025?
When and where will Zentalis (ZNTL) present their ASCO 2025 poster?
What is the potential market position of Zentalis (ZNTL) azenosertib?
What is the target patient population for Zentalis (ZNTL) azenosertib trial?
